Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs) and…
Elanco’s Zenrelia (ilunocitinib) Wins Positive CVMP Opinion, Paving the Way for EU Approval and Market Release Elanco Animal Health Incorporated (NYSE: ELAN) today announces a significant milestone in its ongoing expansion into veterinary care: the Committee for Veterinary Medicinal Products…
mRNA Technology Transfer Programme Moves Into Phase 2.0, Boosting Sustainable Local Vaccine Manufacturing and Global Health Security In parallel with the G20 Health Working Group meeting, global health leaders and stakeholders are gathering in Johannesburg, South Africa, to accelerate the…
Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced a significant new collaboration aimed at strengthening Japan’s role as…
Amgen and Barry Sanders Raise Awareness About “Bad Cholesterol” in Documentary Highlighting Cardiovascular Disease Crisis in America Amgen today announced the launch of The Making of a Heart Attack, a powerful documentary that aims to illuminate the growing cardiovascular disease…
FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®…
Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Clinical Results in Large B-Cell Lymphoma Johnson & Johnson recently presented promising first-in-human data from its ongoing Phase 1b study evaluating JNJ-90014496 (JNJ-4496) — an investigational, dual-targeting, autologous chimeric antigen…
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing…
Bristol Myers Squibb Highlights Targeted Protein Degradation Advances, Including CELMoD Agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy Bristol Myers Squibb today revealed new and updated data from its growing portfolio of targeted protein degradation programs during…
Merck Animal Health Wins Positive EU CVMP Opinion for NUMELVI (atinvicitinib) Tablets for Dogs Merck Animal Health, a division of Merck & Co known as MSD Animal Health outside the United States and Canada today announced a significant milestone in…
Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and promising Phase 1b data demonstrating strong antileukemic activity and a…
Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the dosing of the first patient in the Phase 3 REVEAL clinical trial, marking a…